Profile Picture
  • All
  • AI Mode
  • Web
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
  • Notebook
  • Top stories
  • 2026 Election
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost recent
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

Cartesian, Therapeutics

Digest more
Top News
Overview
Highlights
 · 6h
Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update
NEWARK, CA / ACCESS Newswire / / Protagonist Therapeutics (Nasdaq:PTGX) (“Protagonist” or “the Company”) today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

Continue reading

MarketScreener · 23h
Cartesian Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026
 · 22h
Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
 · 1d
Compass Diversified Reports Third Quarter 2026 Financial Results
Income from Continuing Operations of $23.2 million, compared with a loss of $86.7 million in the prior-year period

Continue reading

 · 7h
Intrusion Inc. to Announce Third Quarter 2026 Financial Results on Thursday, November 12, 2026
USA Today · 1d
FRP Holdings, Inc. Reports Fiscal 2026 Third Quarter Results
 · 1d
Alto Ingredients, Inc. Reports Third Quarter 2026 Results
“We delivered positive gross profit, income from operations, net income and adjusted EBITDA for the third quarter demonstrating the earnings power of our core operations with 45Z tax credit earnings a...

Continue reading

 · 6h
Imperial Reports Third Quarter 2026 Financial Results
 · 6h
Interfor Reports Q3’26 Results
Yahoo Finance
11mon

Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices ...
irblog.prnewswire.com
5y

Cartesian Therapeutics Strengthens Leadership Team With Hire of Miloš Miljković, M.D., as Chief Medical Officer

GAITHERSBURG, Md., Sept. 28, 2021 /PRNewswire/ -- Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced the hire of Miloš Miljković, M.D., as Vice ...
7d

Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement

Cartesian Therapeutics is expanding Descartes-08 into myositis indications and pursuing an in vivo CAR-T approach. I rate RNAC stock as Buy. Click to read my full update.
FINVIZ
2d

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee.
irblog.prnewswire.com
5y

Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer

GAITHERSBURG, Md., Feb. 22, 2021 /PRNewswire/ -- Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering mRNA-engineered cell therapy in and beyond oncology, today announced that it has initiated a Phase 2a clinical ...
Seeking Alpha
1y

Cartesian Therapeutics: Uncertainty Remains

Cartesian Therapeutics, Inc. is a Gaithersburg, Maryland based clinical-stage biopharmaceutical concern focused on developing mRNA cell therapies for the treatment of autoimmune diseases. It is advancing two clinical programs: Descartes-08 for MG and ...
Medindia
5y

Cartesian Therapeutics Announces Clinical Responses in First Cohort of Phase 1b/2a Trial in Myasthenia Gravis

-- In cohort of three patients intended to test safety, all patients showed full-class improvement in the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification and substantial improvement in Myasthenia Gravis Composite scale. The cohort ...
Yahoo Finance
10mon

Factorial and Cartesian Growth Corporation III (Nasdaq: CGCT) Announce Business Combination Agreement to Accelerate Commercialization of Solid-State Battery Technology

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices ...
2026 Midterm Election
View the latest election news
See full coverage
  • Privacy
  • Terms